DGIdb - SRC Gene Record

SRC 6714 Druggable GenomeClinically Actionable

Alternate Names:

6714
SRC PROTO-ONCOGENE, NON-RECEPTOR TYROSINE KINASE
SRC
ASV
SRC1
THC6
c-SRC
p60-Src
190090
11283
ENSG00000197122
OTTHUMG00000032417
P12931
SRC_HUMAN
PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
pp60c-src
Proto-oncogene c-Src
PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (EC 2.7.1.112) (P60-SRC) (C-SRC). [SOURCE:UNIPROT/SWISSPROT;ACC:P12931]
T85943

Gene Info:

Human Readable Name	DRUGGABLE GENOME
Human Readable Name	KINASE
Interpro Acc	IPR001245
Uniprot Evidence	1: Evidence at protein level
Interpro Type	Domain
Interpro Name	Serine-threonine/tyrosine-protein kinase catalytic domain
Uniprot Status	Swiss-Prot
Interpro Short Name	Ser-Thr/Tyr_kinase_cat_dom
CancerCommons Reported Gene Name	SRC
Target Main Class	Enzymes
Target Subclass	2.7.10.2
Initial Gene Query	SRC
Counted Citations from 1950-2000	17440
Target Class	Enzymes
Target Subclass	EC:2.7.10.2
Gene Biotype	PROTEIN_CODING

(20 More Sources)

Gene Categories: Category Details

KINASE
TYROSINE KINASE
DRUGGABLE GENOME
CLINICALLY ACTIONABLE
TRANSCRIPTION FACTOR

Publications:

Powles et al., 2016, A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)., Ann. Oncol.
Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.
Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet
Nam et al., 2005, Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells., Cancer Res.
Kamath et al., 2008, Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL., Cancer Chemother. Pharmacol.
Quintás-Cardama et al., 2006, Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib., Future Oncol
Schittenhelm et al., 2006, Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies., Cancer Res.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Serrels et al., 2006, Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib., Mol. Cancer Ther.
Getlik M et al., 2009, Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc., J Med Chem
Zhang CH et al., 2015, Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer., J Med Chem
Beadnell et al., 2016, The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer., Mol. Cancer Ther.
Du et al., 2009, Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy., Nat. Biotechnol.
Saha et al., 2016, Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma., Cancer Discov
Gilani et al., 2016, UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer., Clin. Cancer Res.
Crystal et al., 2014, Patient-derived models of acquired resistance can identify effective drug combinations for cancer., Science
Anbalagan et al., 2012, Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts., Mol. Cancer Ther.
Carraro F et al., 2006, Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation., J Med Chem
Kiss R et al., 2009, Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening., Bioorg Med Chem Lett
Wittmann et al., 2005, Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases., J. Pharmacol. Exp. Ther.
Nam et al., 2016, Src as a Therapeutic Target in Biliary Tract Cancer., Mol. Cancer Ther.
Pan et al., 2015, Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy., PLoS ONE
O'Hare et al., 2009, AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance., Cancer Cell
Noronha G et al., 2007, Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays., Bioorg Med Chem Lett
Ben Amor N et al., 2007, Characterization of the intracellular mechanisms involved in the antiaggregant properties of cinnamtannin B-1 from bay wood in human platelets., J Med Chem
Graham Robinett R et al., 2007, The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors., Bioorg Med Chem Lett
Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.
Yang et al., Effects of doxorubicin on pp60c-src kinase activity in polyoma virus MT antigen transformed cells., Anticancer Res.
McDonald O et al., 2006, Aza-stilbenes as potent and selective c-RAF inhibitors., Bioorg Med Chem Lett

CINNAMTANNIN B1 SRC

Interaction Score: 2.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17602466

Sources:
DTC
CHEMBL230686 SRC

Interaction Score: 2.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17113292

Sources:
DTC
KX2-391 SRC

Interaction Score: 2.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
22784709

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions
GW459057A SRC

Interaction Score: 1.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16890436

Sources:
DTC
BOSUTINIB SRC

Interaction Score: 1.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase SRC inhibitor

Direct Interaction yes

Notes

PMIDs:
27196758

Sources:
TALC TdgClinicalTrial JAX-CKB ChemblInteractions TTD
KX2-361 SRC

Interaction Score: 1.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
TTD
SARACATINIB SRC

Interaction Score: 0.64

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

combination therapy Cediranib + Saracatinib

Indication/Tumor Type renal clear cell carcinoma

PMIDs:
25394791 26802156

Sources:
TALC MyCancerGenome JAX-CKB ChemblInteractions TTD
AZD-0424 SRC

Interaction Score: 0.55

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase SRC inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
AZM-475271 SRC

Interaction Score: 0.55

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Tyrosine-protein kinase SRC inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
GW559768X SRC

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17884497

Sources:
DTC
CHEMBL219557 SRC

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
DASATINIB SRC

Interaction Score: 0.32

Interaction Types & Directionality:

multitarget

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction SRC inhibitor

Novel drug target Established target

PMIDs:
16230377 17429625 17155893 16397263 11752352 17148760 19462975 25835317 27222538 19098899 27231123 27154914

Sources:
TALC DTC TdgClinicalTrial JAX-CKB ChemblInteractions TEND CancerCommons TTD
XL-228 SRC

Interaction Score: 0.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name XL228

Novel drug target Established target

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions
ANLOTINIB SRC

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
CERITINIB SRC

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type resistant

Approval Status Preclinical

PMIDs:
25394791

Sources:
JAX-CKB
PONATINIB SRC

Interaction Score: 0.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Pdx

Response Type no benefit

PMIDs:
26270481 19878872

Sources:
TdgClinicalTrial JAX-CKB
CRENOLANIB SRC

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
MASITINIB SRC

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name masitinib, AB1010

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD
NINTEDANIB SRC

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18559524 31016670

Sources:
TALC
JNJ-26483327 SRC

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase SRC inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CHEMBL406845 SRC

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16509573 19447617

Sources:
DTC
DORAMAPIMOD SRC

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BIRB-796 + Dasatinib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
27154914

Sources:
JAX-CKB
LAPATINIB SRC

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Indication/Tumor Type urinary bladder cancer

Response Type no benefit

PMIDs:
26270481

Sources:
JAX-CKB
CEDIRANIB SRC

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type no benefit

combination therapy Cediranib + Saracatinib

Indication/Tumor Type renal clear cell carcinoma

PMIDs:
26802156

Sources:
DTC JAX-CKB
TG100-801 SRC

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction SRC inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
SELUMETINIB SRC

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Dasatinib + Selumetinib

Indication/Tumor Type thyroid cancer

Response Type sensitive

PMIDs:
27222538

Sources:
JAX-CKB
CRIZOTINIB SRC

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung cancer

Response Type resistant

Approval Status Preclinical

PMIDs:
None found

Sources:
JAX-CKB
TRAMETINIB SRC

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type thyroid cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
27222538

Sources:
JAX-CKB
ENMD-2076 SRC

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name ENMD-2076

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
MLN-8054 SRC

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ENMD-981693 SRC

Interaction Score: 0.04

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction SRC inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CLOZAPINE SRC

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15659539

Sources:
NCI
GW843682X SRC

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
HESPERADIN SRC

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
19035792

Sources:
DTC
GEMCITABINE SRC

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bosutinib + Gemcitabine

Indication/Tumor Type biliary tract cancer

Response Type sensitive

PMIDs:
27196758

Sources:
JAX-CKB
ALISERTIB SRC

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OSI-632 SRC

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DOXORUBICIN SRC

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7532928

Sources:
NCI
KENPAULLONE SRC

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PACLITAXEL SRC

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy KX2-391 + Paclitaxel

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
22784709

Sources:
JAX-CKB
ALSTERPAULLONE SRC

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ILORASERTIB SRC

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction SRC inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
DTC ChemblInteractions
PD-0166285 SRC

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Tyrosine-protein kinase SRC inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
VANDETANIB SRC

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase SRC inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ENTRECTINIB SRC

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
GW441756X SRC

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LINIFANIB SRC

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TOZASERTIB SRC

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN SRC

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bosutinib + Cisplatin

Indication/Tumor Type biliary tract cancer

Response Type sensitive

PMIDs:
27196758

Sources:
JAX-CKB
R-406 SRC

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
RG-1530 SRC

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DOVITINIB SRC

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CYC-116 SRC

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TAE-684 SRC

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PF-00562271 SRC

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CENISERTIB SRC

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

Ensembl: ENSG00000197122
- Version: 101_38
Alternate Names:

SRC Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TdgClinicalTrial: P12931
- Version: January-2014
Alternate Names:

SRC Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:2.7.10.2

Publications:
HopkinsGroom: P12931
- Version: 11-September-2012
Alternate Names:

ENSG00000197122 Ensembl Gene Id

P12931 Uniprot Accession

SRC Uniprot Gene Name

Gene Info:

Human Readable Name DRUGGABLE GENOME

Human Readable Name KINASE

Interpro Acc IPR001245

Gene Categories:

KINASE, DRUGGABLE GENOME

Publications:
TEND: P12931
- Version: 01-August-2011
Alternate Names:

SRC Gene Symbol

SRC_HUMAN Uniprot Id

6714 Entrez Gene Id

Gene Info:

Target Main Class Enzymes

Target Subclass 2.7.10.2

Publications:
BaderLabGenes: SRC
- Version: February-2014
Alternate Names:

6714 Entrez Gene ID

Gene Info:

Initial Gene Query SRC

Counted Citations from 1950-2000 17440

Gene Categories:

KINASE

Publications:
RussLampel: ENSG00000197122
- Version: 26-July-2011
Alternate Names:

PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (EC 2.7.1.112) (P60-SRC) (C-SRC). [SOURCE:UNIPROT/SWISSPROT;ACC:P12931] Description

SRC Display Id

ENSG00000197122 Ensembl Gene Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:
CancerCommons: SRC
- Version: 25-July-2013
Alternate Names:

6714 Entrez Gene ID

Gene Info:

CancerCommons Reported Gene Name SRC

Publications:

JAX-CKB: SRC

Version: 27-September-2017

Alternate Names:

6714 CKB Entrez Id

SRC CKB Gene Synonym

ASV CKB Gene Synonym

Gene Info:

Publications:

Pan et al., 2015, Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy., PLoS ONE

Nam et al., 2016, Src as a Therapeutic Target in Biliary Tract Cancer., Mol. Cancer Ther.

Gilani et al., 2016, UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer., Clin. Cancer Res.

NCI: SRC

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Yang et al., Effects of doxorubicin on pp60c-src kinase activity in polyoma virus MT antigen transformed cells., Anticancer Res.

Fuhrer et al., 1996, Activation of Src-family protein tyrosine kinases and phosphatidylinositol 3-kinase in 3T3-L1 mouse preadipocytes by interleukin-11., Exp. Hematol.

Alioua et al., 2002, Coupling of c-Src to large conductance voltage- and Ca2+-activated K+ channels as a new mechanism of agonist-induced vasoconstriction., Proc. Natl. Acad. Sci. U.S.A.

DTC: SRC

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

McDonald O et al., 2006, Aza-stilbenes as potent and selective c-RAF inhibitors., Bioorg Med Chem Lett

Kiss R et al., 2009, Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening., Bioorg Med Chem Lett

Carraro F et al., 2006, Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation., J Med Chem

TALC: C-SRC
- Version: 12-May-2016
Alternate Names:

C-SRC Gene Symbol

Gene Info:

Publications:
MyCancerGenome: SRC
- Version: 20-Jun-2017
Alternate Names:

6714 Entrez Gene Id

SRC MyCancerGenome Gene Symbol

SRC MyCancerGenome Reported Gene Name

Gene Info:

Publications:
TALC: SRC
- Version: 12-May-2016
Alternate Names:

SRC Gene Symbol

Gene Info:

Publications:
HingoraniCasas: ENSG00000197122
- Version: 31-May-2017
Alternate Names:

ENSG00000197122 Gene Symbol

SRC Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
ChemblInteractions: SRC1
- Version: chembl_23
Alternate Names:

SRC1 GENE_SYMBOL

SRC GENE_SYMBOL

Proto-oncogene tyrosine-protein kinase Src UNIPROT

Gene Info:

Publications:
GO: SRC
- Version: 01-February-2022
Alternate Names:

SRC1 GO Gene Synonym

Gene Info:

Gene Categories:

TYROSINE KINASE

Publications:
Tempus: SRC
- Version: 11-November-2018
Alternate Names:

SRC Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
dGene: SRC
- Version: 27-Jun-2013
Alternate Names:

6714 Gene ID

ASV dGene Synonym

SRC1 dGene Synonym

Gene Info:

Gene Categories:

KINASE, TYROSINE KINASE

Publications:
TTD: Proto-oncogene c-Src
- Version: 2020.06.01
Alternate Names:

SRC TTD Gene Abbreviation

T85943 TTD Target ID

Gene Info:

Publications:
Pharos: SRC
- Version: 01-February-2022
Alternate Names:

Proto-oncogene tyrosine-protein kinase Src Gene Name

P12931 UniProt ID

Gene Info:

Gene Categories:

KINASE, TRANSCRIPTION FACTOR

Publications:
MskImpact: SRC
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
FoundationOneGenes: SRC
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: SRC
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Oncomine: SRC
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive
Approval Status	Preclinical

Mechanism of Interaction	Tyrosine-protein kinase SRC inhibitor
Direct Interaction	yes
Notes

Notes
combination therapy	Cediranib + Saracatinib
Indication/Tumor Type	renal clear cell carcinoma

Direct Interaction	yes
Mechanism of Interaction	SRC inhibitor
Novel drug target	Established target

Indication/Tumor Type	Advanced Solid Tumor
Response Type	resistant
Approval Status	Preclinical

Evidence Type	Actionable
Approval Status	Preclinical - Pdx
Response Type	no benefit

Trial Name	masitinib, AB1010
Novel drug target	Established target

combination therapy	BIRB-796 + Dasatinib
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive

combination therapy	Dasatinib + Selumetinib
Indication/Tumor Type	thyroid cancer
Response Type	sensitive

Indication/Tumor Type	lung cancer
Response Type	resistant
Approval Status	Preclinical

multitarget
inhibitor (inhibitory)

combination therapy	Bosutinib + Gemcitabine
Indication/Tumor Type	biliary tract cancer
Response Type	sensitive

combination therapy	KX2-391 + Paclitaxel
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive

combination therapy	Bosutinib + Cisplatin
Indication/Tumor Type	biliary tract cancer
Response Type	sensitive

ENSG00000197122	Ensembl Gene Id
P12931	Uniprot Accession
SRC	Uniprot Gene Name

PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (EC 2.7.1.112) (P60-SRC) (C-SRC). [SOURCE:UNIPROT/SWISSPROT;ACC:P12931]	Description
SRC	Display Id
ENSG00000197122	Ensembl Gene Id

6714	Entrez Gene Id
SRC	MyCancerGenome Gene Symbol
SRC	MyCancerGenome Reported Gene Name

SRC1	GENE_SYMBOL
SRC	GENE_SYMBOL
Proto-oncogene tyrosine-protein kinase Src	UNIPROT

Proto-oncogene tyrosine-protein kinase Src	Gene Name
P12931	UniProt ID

SRC Gene Record

SRC 6714 Druggable GenomeClinically Actionable

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17602466

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17113292

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type triple-receptor negative breast cancer Response Type sensitive Approval Status Preclinical

PMIDs: 22784709

Sources: TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16890436

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tyrosine-protein kinase SRC inhibitor Direct Interaction yes Notes

PMIDs: 27196758

Sources: TALC TdgClinicalTrial JAX-CKB ChemblInteractions TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes combination therapy Cediranib + Saracatinib Indication/Tumor Type renal clear cell carcinoma

PMIDs: 25394791 26802156

Sources: TALC MyCancerGenome JAX-CKB ChemblInteractions TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Tyrosine-protein kinase SRC inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Tyrosine-protein kinase SRC inhibitor

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17884497

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: multitarget inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction SRC inhibitor Novel drug target Established target

PMIDs: 16230377 17429625 17155893 16397263 11752352 17148760 19462975 25835317 27222538 19098899 27231123 27154914

Sources: TALC DTC TdgClinicalTrial JAX-CKB ChemblInteractions TEND CancerCommons TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name XL228 Novel drug target Established target

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type resistant Approval Status Preclinical

PMIDs: 25394791

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Pdx Response Type no benefit

PMIDs: 26270481 19878872

Sources: TdgClinicalTrial JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info: Trial Name masitinib, AB1010 Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

Interaction Types & Directionality:

n/a

PMIDs:
17602466

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
17113292

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
22784709

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
16890436

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase SRC inhibitor

Direct Interaction yes

Notes

PMIDs:
27196758

Sources:
TALC TdgClinicalTrial JAX-CKB ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

combination therapy Cediranib + Saracatinib

Indication/Tumor Type renal clear cell carcinoma

PMIDs:
25394791 26802156

Sources:
TALC MyCancerGenome JAX-CKB ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase SRC inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Tyrosine-protein kinase SRC inhibitor

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
17884497

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

multitarget

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction SRC inhibitor

Novel drug target Established target

PMIDs:
16230377 17429625 17155893 16397263 11752352 17148760 19462975 25835317 27222538 19098899 27231123 27154914

Sources:
TALC DTC TdgClinicalTrial JAX-CKB ChemblInteractions TEND CancerCommons TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name XL228

Novel drug target Established target

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type resistant

Approval Status Preclinical

PMIDs:
25394791

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Pdx

Response Type no benefit

PMIDs:
26270481 19878872

Sources:
TdgClinicalTrial JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name masitinib, AB1010

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
18559524 31016670

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Tyrosine-protein kinase SRC inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
16509573 19447617

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BIRB-796 + Dasatinib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
27154914

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a